Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C20H21N7O6.2Na |
| Molecular Weight | 501.4036 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].NC1=NC2=C(N3CN(CC3CN2)C4=CC=C(C=C4)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C(=O)N1
InChI
InChIKey=DIAFTFLDTRCVOX-RIWFDJIXSA-L
InChI=1S/C20H23N7O6.2Na/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29;;/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31);;/q;2*+1/p-2/t12?,13-;;/m0../s1
Folitixorin, a thymidylate synthase inhibitor is a substrate used by the enzyme methylenetetrahydrofolate reductase (MTHFR) to generate 5-methyltetrahydrofolate. Folitixorin was studied in clinical trials for the treatment of breast cancer, metastatic colorectal cancer and for the treatment of advanced pancreatic cancer. Folitixorin had been granted orphan drug status for the treatment of pancreatic cancer in both the U.S. and EU. However, further development of this drug was discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism. | 2008-01 |
|
| Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? | 2006-06 |
|
| A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. | 1995-05 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
136245568
Created by
admin on Mon Mar 31 18:26:58 GMT 2025 , Edited by admin on Mon Mar 31 18:26:58 GMT 2025
|
PRIMARY | |||
|
133978-76-4
Created by
admin on Mon Mar 31 18:26:58 GMT 2025 , Edited by admin on Mon Mar 31 18:26:58 GMT 2025
|
PRIMARY | |||
|
172V4KO1N5
Created by
admin on Mon Mar 31 18:26:58 GMT 2025 , Edited by admin on Mon Mar 31 18:26:58 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
